Is there a need for a new generation of vaccines against pertussis?

Expert Opinion on Emerging Drugs

Volumn 11, Issue 2, 2006, Pages 195-205

  Storsaeter, Jann ^a   Wolter, Joanne ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NONE

Author keywords

Bordetella pertussis; DNA vaccine; Mucosal vaccine; Pertussis vaccine; Virulence factors

Indexed keywords

ACELLULAR VACCINE; ADENYLATE CYCLASE TOXIN; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; BACTERIAL PROTEIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; DTPA BOOSTRIX; DTPA IPV BOOSTRIX; EXOTOXIN; HEMAGGLUTININ; INACTIVATED VACCINE; LIPID A; LIPOPOLYSACCHARIDE; LIVE VACCINE; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; POLYGLACTIN; PROTEIN ANTIBODY; PROTEIN BRKA; UNCLASSIFIED DRUG; WHOLE CELL VACCINE;

ABSENCE OF SIDE EFFECTS; BACTERICIDAL ACTIVITY; BACTERIUM ADHERENCE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIMB SWELLING; META ANALYSIS; MORBIDITY; NEUTROPHIL; NONHUMAN; PERTUSSIS; PHAGOCYTE; PHAGOCYTOSIS; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; BORDETELLA PERTUSSIS; HUMANS; PERTUSSIS VACCINE; VACCINATION; VACCINES, DNA; WHOOPING COUGH;

EID: 33646553065     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.11.2.195     Document Type: Review

References (103)

1. MATTOO S, CHERRY JD: Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. (2005) 18(2):326-382. A comprehensive review of all aspects of pertussis disease.
2. EDWARDS KM: Overview of pertussis. Focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr. Infect. Dis. J. (2005) 24(6S):S104-S108.
3. CHERRY JD: The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics (2005) 115:1422-1427. Recent overview of epidemiology.
4. FORSYTH KD, CAMPINS-MARTI M, CARO J et al.; GLOBAL PERTUSSIS INITIATIVE: New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clin. Infect. Dis. (2004) 39:1802-1809. Recommendations for future vaccination policy from a group of experts.
5. HALPERIN SA: Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implication for the United States. Pediatr. Infect. Dis. J. (2005) 24(6S):S141-S146.
6. BARON S, NJAMKEPO E, GRIMPREL E et al.: Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr. Infect. Dis. J. (1998) 17(5):412-418.
7. CHERRY JD: Historical review of pertussis and the classical vaccine. J. Infect. Dis. (1996) 174(Suppl. 3):S259-S263.
8. WIRSING VON KÖNIG CH, HALPERIN S, RIFFELMANN M, GUISO N: Pertussis of adults and infants. Lancet Infect. Dis. (2002) 2(12):744-750.
9. SALMASO S, MASTRANTONIO P, TOZZI AE et al.: Stage III Working Group. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics (2001) 108(5):E81.
10. GRIMPREL E, BÉGUÉ P, ANJAK I, NJAMKEPO E, FRANCOIS P, GUISO N: Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin. Diagn. Lab. Immunol. (1996) 3(1):93-97.
11. WENDELBOE AM, VAN RIE A, SALMASO S, ENGLUND JA: Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J. (2005) 24(5Suppl.):S58-S61.
12. LUGAUER S, HEININGER U, CHERRY JD, STEHR K: Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur. J. Pediatr. (2002) 161(3):142-146.
13. LACOMBE K, YAM A, SIMONDON K, PINCHINAT S, SIMONDON F: Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine (2004) 23(5):623-628.
14. AOYAMA T, HARASHIMA M, NISHIMURA K, SAITO Y: Outbreak of pertussis in highly immunized adolescents and its secondary spread to their families. Acta. Pediatr. Jpn. (1995) 37:321-324.
15. CROWCROFT NS, BRITTO J: Whooping cough - a continuing problem. Br. Med. J. (2002) 324(7353):1537-1538.
16. ANDREWS R, HERCEG A, ROBERTS C: Pertussis notifications in Australia 1991 to 1997. Comm. Dis. Intell. (1997) 21:145-148.
17. MORRIS A, ELLIOTT E, MCINTYRE P, MASSIE J, RIDLEY G, MCENIERY G; CONTRIBUTORS TO THE AUSTRALIAN PAEDIATRIC SURVEILLANCE UNIT (APSU): Hospitalized pertussis in infancy. J. Pediatr. Child. Health. (2002) 38:A2.
18. STOJANOV S, LIESE J, BELOHRADSKY B: Hospitalization and complications in children under 2 years of age with Bordetella pertussis infection. Infection (2000) 28:106-110.
19. VITEK C, PASCUAL F, BAUGHMAN A, MURPHY T: Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr. Infect. Dis. J. (2003) 22:628-634.
20. CENTERS FOR DISEASE CONTROL AND PREVENTION: Recommended childhood and adolescent immunization schedule - United States, 2006. MMWR (2005) 54:Q1-Q4.
21. GUSTAVSSON OEA, ROKEN BO, SERRANDER R: An epizootic of whooping cough among chimpanzees in a zoo. Folia Primatologia (1990) 55:45-50.
22. SYUKUDA Y, WATANABE H, SUEHARA A et al.: Aerosol infection test for evaluation of pertussis vaccine. Tokai. J. Exp. Clin. Med. (1988) 13:71-77.
23. WORLD HEALTH ORGANIZATION: Pertussis vaccines - WHO position paper. Wkly. Epidemiol. Rec. (2005) 80:31-39.
24. JEFFERSON T, RUDIN M, DIPIETRANTONJ C: Systematic review of the effects of pertussis vaccines in children. Vaccine (2003) 21(17-18):2003-2014. Meta-analysis of efficacy and safety data comparing whole-cell and different acellular petussis vaccines.
25. ARISTEGUI J, USONIS V, COOVADIA H et al.: Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int. J. Infect. Dis. (2003) 7:143-151.
26. GATCHALIAN S, DOBBELAERE K, HAN HH, BOUTRIAU D: Immunogenicity and safety of 3 doses of a new heptavalent DTPw-HBV/Hib-MenAC vaccine administered to infants at 6, 10 and 14 weeks of age. 14th International Pathogenic Neisseria Conference. Milwaukee, Wisconsin, USA (2004).
27. MILLER E, VURDIEN J, WHITE J: The epidemiology of pertussis in England and Wales. Comm. Dis. Rep. (1992) 2:152-154.
28. SATO Y, SATO H: Development of acellular pertussis vaccines. Biologicals (1999) 27(2):61-69.
29. ROMANUS V, JONSELL R, BERGQUIST SO: Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr. Infect. Dis. J. (1987) 6(4):364-371.
30. SCHNEERSON R, ROBBINS JB, TARANGER J, LAGERGARD T, TROLLFORS B: A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet (1996) 348(9037):1289-1292.
31. ROBBINS JB, SCHNEERSON R, TROLLFORS B et al.: The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J. Infect. Dis. (2005) 191:81-88.
32. STORSAETER J, HALLANDER H, FARRINGTON CP, OLIN P, MOLLBY R, MILLER E: Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish Phase III trial. Vaccine (1990) 8(5):457-461.
33. AD HOC GROUP FOR THE STUDY OF PERTUSSIS VACCINES: Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet (1988) 1(8592):955-960.
34. STORSAETER J, HALLANDER HO, GUSTAFSSON L, OLIN P: Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine (1998) 16:1907-1916. Key evidence for the role of PT, PRN and FIM in protection against pertussis disease.
35. CHERRY JD, GORNBEIN J, HEININGER U, STEHR K: A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine (1998) 16(20):1901-1906. Key evidence for the role of PT, PRN and FIM in protection against pertussis disease.
36. STORSAETER J, HALLANDER HO, GUSTAFSSON L, OLIN P: Low levels of and pertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine (2003) 21:3542-3549.
37. GRANSTROM M, GRANSTROM G: Serological correlates in whooping cough. Vaccine (1993) 11(4):445-448.
38. LINNEMANN CC JR, NASENBENY J: Pertussis in the adult. Ann. Rev. Med. (1977) 28:179-185.
39. GODFROID F, DENOËL P, POOLMAN J: Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? Exp. Rev. Vaccines (2005) 4(5):757-778.
40. WEISS AA, MOBBERLEY PS, FERNANDEZ RC, MINK CM: Characterization of human bactericidal antibodies to Bordetella pertussis. Infect. Immun. (1999) 67(3):1424-1431.
41. OLIVER DC, FERNANDEZ RC: Antibodies to BrkA augment killing of Bordetella pertussis. Vaccine (2001) 20(1-2):235-241.
42. GOTTO JW, ECKHARDT T, REILLY PA et al.: Biochemical and immunological properties of two forms of pertactin, the 69,000-molecular-weight outer membrane protein of Bordetella pertussis. Infect. Immun. (1993) 61(5):2211-2215.
43. HELLWIG SM, RODRIGUEZ ME, BERBERS GA, VAN DE WINKEL JG, MOOI FR: Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J. Infect. Dis. (2003) 188(5):738-742.
44. LIESE JG, MESCHIEVITZ CK, HARZER E et al.: Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J. (1997) 16:1038-1044.
45. MILLS KHG: Immunity to Bordetella pertussis. Microbes Infect. (2001) 3:655-677.
46. GIULIANO M, MASTRANTONIO P, GIAMMANCO A, PISCITELLI A, SALMASO S, WASSILAK SG: Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J. Pediatr. (1998) 132(6):983-988.
47. AUSIELLO CM, LANDE R, URBANI F et al.: Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J. Infect. Dis. (2000) 181:1989-1995.
48. CASSONE A, AUSIELLO CM, URBANI F et al.: Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group. Arch. Pediatr. Adolesc. Med. (1997) 151(3):283-289.
49. WOO EJ, BURWEN DR, GATUMU SNM, BALL R; THE VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS) WORKING GROUP: Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System. Clin. Infect. Dis. (2003) 37:351-358.
50. LOCHT C, ANTOINE R, RAZE D et al.: Bordetella pertussis from functional genomics to intranasal vaccination. Int. J. Med. Microbiol. (2004) 293:583-588.
51. H2 cells. Vaccine (2001) 19(15-16):1940-1950.
52. BELLANTI JA, ZELIGS BJ, MENDEZ DE INOCENCIO J, OMIDVAR BM, OMIDVAR J, AWASUM M: Alternative routes of immunization for prevention of infectious diseases: a new paradigm for the 21st century. Allergy Asthma. Proc. (2001) 22:173-176.
53. PARTIDOS CD, BEIGNON AS, BROWN F, KRAMER E, BRIAND JP, MULLER S: Applying peptide antigens onto bare skin: induction of humoral and cellular immune responses and potential for vaccination. J. Control. Release (2002) 85:27-34.
54. RYAN M, MURPHY G, RYAN E et al.: Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology (1998) 93:1-10.
55. ZEPP F, KNUF M, HABERMEHL P et al.: Cell-mediated immunity after pertussis vaccination and after natural infection. Dev. Biol. Stand. (1997) 89:307-314.
56. SIEGRIST CA: Neonatal and early life vaccinology. Vaccine (2001) 19(25-26):3331-3346.
57. WEINGART CL, KEITEL WA, EDWARDS KM, WEISS AA: Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults. Infect. Immun. (2000) 68(12):7175-7179.
58. HEININGER U, STEHR K, SCHMITT-GROHE S et al.: Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr. Infect. Dis. J. (1994) 13(4):306-309.
59. HARVILL ET, PRESTON A, COTTER PA, ALLEN AG, MASKELL DJ, MILLER JF: Multiple roles for Bordetella lipopolysaccharide molecules during respiratory tract infection. Infect. Immun. (2000) 68(12):6720-6728.
60. H1 cells. Infect. Immun. (1996) 64(12):5295-5301.
61. WEINGART CL, WEISS AA: Bordetella pertussis virulence factors affect phagocytosis by human neutrophils. Infect. Immun. (2000) 68(3):1735-1739.
62. H2 and regulatory T cells. Infect. Immun. (2004) 72(3):1568-1579.
63. WEINGART CL, MOBBERLEY-SCHUMAN PS, HEWLETT EL, GRAY MC, WEISS AA: Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils. Infect. Immun. (2000) 68(12):7152-7155.
64. GUISO N, ROCANCOURT M, SZATANIK M, ALONSO JM: Bordetella adenylate cyclase is a virulence associated factor and an immunoprotective antigen. Microb. Pathog. (1989) 7(5):373-380.
65. GUISO N, SZATANIK M, ROCANCOURT M: Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization. Microb. Pathog. (1991) 11(6):423-431.
66. CHERRY JD, XING DX, NEWLAND P, PATEL K, HEININGER U, CORBEL MJ: Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. Clin. Infect. Dis. (2004) 38:502-507.
67. RENNELS MB: Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Sem. Ped. Infect. Dis. (2003) 14(3):196-198.
68. SCHEIFELE DW, HALPERIN SA, FERGUSON AC: Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin test with vaccine antigens. Vaccine (2001) 19:4720-4726.
69. SOUTHERN J, ANDREWS N, BURRAGE M, MILLER E: Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine (2005) 23(29):3829-3835.
70. RENNELS MB, DELORIA MA, PICHICHERO ME et al.: Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics (2000) 105(1):e12.
71. RELYVELD EH, BIZZINI B, GUPTA RK: Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine (1998) 16(9-10):1016-1023.
72. The Australian Immunisation Handbook, 8th edn. National Health & Medical Research Council, Canberra, Australia (2003).
73. CHERRY JD: The protein content of diphtheria-tetanus-toxoids-acellular pertussis vaccines and an emerging clinical problem. J. Infect. Dis. (2005) 191:1386-1388.
74. ROBERT KOCH-INSTITUT: Empfehlung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut zur Pertussis-Schutzimpfung. Epidemiologisches Bulletin (2006) 3:21-23.
75. VERGARA R, TREGNAGHI M, USSHER J et al.: Reduced-antigen-content- diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur. J. Pediatr. (2005) 164(6):377-382.
76. ALONSO S, REVENEAU N, PETHE K, LOCHT C: Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role. Infect. Immun. (2002) 70(8):4142-4147.
77. EDWARDS KM, MEADE BD, DECKER MD et al.: Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics (1995) 96(3 Pt 2):548-557.
78. DECKER MD, EDWARDS KM, STEINHOFF MC et al.: Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics (1995) 96(3 Pt 2):557-566.
79. VAN BUYNDER PG, OWEN D, VURDIEN JE, ANDREWS NJ, MATTHEWS RC, MILLER E: Bordetella pertussis surveillance in England and Wales: 1995-7. Epidemiol. Infect. (1999) 123(3):403-411.
80. LINDBLAD EB: Aluminium adjuvants - in retrospect and prospect. Vaccine (2004) 22(27-28):3658-3668.
81. JEFFERSON T, RUDIN M, DI PIETRANTONJ C: Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect. Dis. (2004) 4(2):84-90.
82. THEETEN H, VAN DAMME P, HOPPENBROUWERS K et al.: Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine (2005) 23(12):1515-1521.
83. DENOËL P, POOLMAN J, CARLETTI G, VEITCH K: Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection. Vaccine (2002) 20(19-20):2551-2555.
84. DEL GIUDICE G, PODDA A, RAPPUOLI R: What are the limits of adjuvanticity? Vaccine (2001) 20(Suppl. 1):S38-S41.
85. HUNTER RL: Overview of vaccine adjuvants: present and future. Vaccine (2002) 20(Suppl. 3):S7-S12.
86. PETROVSKY N, AGUILAR JC: Vaccine adjuvants: current state and future trends. Immunol. Cell. Biol. (2004) 82(5):488-496.
87. DONNELLY JJ, WAHREN B, LIU MA: DNA vaccines: progress and challenges. J. Immunol. (2005) 175(2):633-639. Review of current knowledge.
88. KAMACHI K, KONDA T, ARAKAWA Y: DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice. Vaccine (2003) 21(31):4609-4615.
89. MIELCAREK N, DEBRIE A-S, RAZE D et al.: Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. Vaccine (2005) (In Press).
90. LOCHT C, ANTOINE R, RAZE D et al.: Bordetella pertussis: from functional genomics to intranasal vaccination. Int. J. Med. Microbiol. (2004) 293:583-588.
91. LI WAN, PO A: Non-parenteral vaccines have not lived up to their initial promise because of side effects. Br. Med. J. (2004) 329:62-63.
92. CENTERS FOR DISEASE CONTROL AND PREVENTION: General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR (2002) 51(RR-2):1-35.
93. HEALY CM, MUNOZ FM, RENCH MA, HALASA NB, EDWARDS KM, BAKER CJ: Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J. Infect. Dis. (2004) 190:335-340.
94. RODUIT C, BOZZOTTI P, MIELCAREK N et al.: Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infect Immun. (2002) 70(7):3521-3528. First evidence in the neonatal mouse model that acellular vaccination at birth may be successful.
95. BELLONI C, DE SILVESTRIA, TINELLI C et al.: Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics (2003) 111(5Pt 1):1042-1045. First evidence in humans for successful priming by acellular pertussis vaccination at birth.
96. LAMBERT PH, LIU M, SIEGRIST CA: Can successful vaccines teach us how to induce efficient protective immune responses? Nature. Med. Supp. (2005) 11:S54-S62.
97. ADAMSON PC, WU TC, MEADE BD, RUBIN M, MANCLARK CR, PIZZO PA: Pertussis in a previously immunized child with human immunodeficiency infection. J. Pediatr. (1989) 115:589-592.
98. ROSANELLI K, FALK W: Die orale Pertussisimpfung (in German). Pädiatrie und Pädologie. (1985) 20:95-102.
99. HAUGAN A, XUANG THI, DAO P et al.: Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines. Vaccine (2003) 22(1):7-14.
100. PROVENZANO RW, WETTERLOW LH, SULLIVAN CL: Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of birth. N. Engl. J. Med. (1965) 273(18):959-965.
101. LEVINE MM, SZTEIN MB: Vaccine development strategies for improving immunization: the role of modern immunology. Nature Immunol. (2004) 5:460-464. A general review of future technologies for vaccination.
102. HUANG CC, CHEN PM, KUO JK et al.: Experimental Whooping cough. N. Engl. J. Med. (1962) 266:105-111.
103. WARD JI, CHERRY JD, CHANG SJ et al.: Efficacy of an acellular pertussis vaccine among adolescents and adults. N. Engl. J. Med. (2005) 353:1555-1563.